Oncology
Palleon’s lead program, E-602, is a first-in-class engineered human genetic fusion from Palleon’s EAGLE platform. The EAGLE (Enzyme-Antibody Glycan- Editing) platform enables creation of novel biological therapeutics by genetic fusion of human sialidase with human monoclonal antibodies. E-602 is designed to desialylate both immune cells and tumor cells.
B7H3-Sialidase is a novel glycan-editing therapeutic from Palleon’s EAGLE platform. The EAGLE (Enzyme-Antibody Glycan-Editing) platform enables creation of novel biological therapeutics by genetic fusion of human sialidase with human monoclonal antibodies. B7H3-Sialidase is designed to enhance the desialylation of both tumor cells and T cells that express B7H3.
In June 2022 Palleon entered into a strategic collaboration with Henlius to co-develop targeted sialidase molecules. Under the terms of the agreement, Palleon will perform research and the parties will then share preclinical and global clinical development responsibilities and costs for B7H3-Sialidase. Henlius has an exclusive license to B7H3-Sialidase in Greater China, while Palleon retains all other global rights.
